EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study

Thibaut Gelé iD, Daniel Atwine, Elisabeth Baudin, Winnie Muyindike iD, Kenneth Mworozi, Racheal Kyohairwe, Keneth Kananura, Susan Logoose, Dan Nyehangane, Deborah K T Nanjebe, Valérie Furlan, Anne-Marie Taburet und 3 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf319 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Thibaut Gelé und 14 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, HIV Infections, Antitubercular Agents. Die Arbeit nennt 43 Literaturangaben. Gefördert von: ANRS, Maladies infectieuses émergentes, Médecins Sans Frontières.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment duration. Although previous data among patients with HIV–TB coinfection has shown that doubling rifampicin dosing had a small effect on EFV concentrations, its effect on the pharmacokinetics (PK) of antituberculosis drugs remains lacking in this population.

Objectives

To compare the PK of rifampicin and isoniazid with and without EFV co-administration in patients with HIV–TB coinfection using two rifampicin dosing regimens (10 and 20 mg/kg/day) and EFV dosing (600 and 800 mg q24h).

Methods

Ninety-seven patients were assigned to three arms in a randomized clinical trial conducted in Uganda. Plasma concentrations of rifampicin, isoniazid, and acetyl-isoniazid were measured. PK parameters were estimated, and statistical comparisons were made using geometric mean ratios, 90% CIs and the pre-set 0.80–1.25 interval.

Results

Doubling rifampicin dosing increased its Cmax and AUClast almost 3-fold. Adding EFV decreased rifampicin AUClast by 34%–40%. Isoniazid AUClast was unaffected with EFV 600 mg q24h but decreased with EFV 800 mg q24h by 23%. EFV increased acetyl-isoniazid concentrations, suggesting enhanced acetylation activity. At 10 mg/kg of rifampicin, 88% of patients had Cmax below the therapeutic range. However, at 20 mg/kg of rifampicin, 87% of patients achieved therapeutic concentrations, ensuring effective treatment.

Conclusions

The study highlights the importance of adjusting rifampicin dosing to achieve therapeutic levels in patients with coinfection. Doubling rifampicin dosing in patients with HIV–TB coinfection increases the percentage of patients with Cmax within the therapeutic range. Additionally, while EFV slightly affects rifampicin and isoniazid PK, these changes are not clinically significant, supporting the efficacy and safety of the combined regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinIsoniazidHIV InfectionsAntitubercular AgentsBenzoxazinesCoinfectionTuberculosisAnti-HIV AgentsHumansMaleFemaleAdultUgandaCyclopropanesAlkynesMiddle AgedYoung AdultPlasmaDrug Interactions

Substanzen

RifampinIsoniazidAntitubercular AgentsBenzoxazinesCyclopropanesefavirenzAlkynesAnti-HIV Agents

Autor:innen und Institutionen

  • Service de Pharmacie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.
  • Epicentre, PO Box 1956, Mbarara, Uganda.
  • SRF Research and Training Centres, PO Box 422317, Mbarara, Uganda.
  • Epicentre-Médecins Sans Frontières, 34, avenue Jean Jaurès, 75019 Paris, France.
  • Mbarara Regional Referral Hospital, Mbarara, Uganda.
  • Service de Pharmacologie-Toxicologie, AP-HP. Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

ORCID-Profile: Thibaut Gelé, Winnie Muyindike, Maryline Bonnet, Aurélie Barrail-Tran

Förderung

  • ANRS
  • Maladies infectieuses émergentes
  • Médecins Sans Frontières

Zitieren

APA

Gelé, T., Atwine, D., Baudin, E., Muyindike, W., Mworozi, K., Kyohairwe, R., Kananura, K., Logoose, S., Nyehangane, D., Nanjebe, D. K. T., Furlan, V., Taburet, A. M., Bonnet, M., Barrail-Tran, A., & ANRS12292 Rifavirenz study group (2025). Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf319

Vancouver

Gelé T, Atwine D, Baudin E, Muyindike W, Mworozi K, Kyohairwe R, et al. Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf319

BibTeX
@article{Gel2025,
  author = {Gelé, Thibaut and Atwine, Daniel and Baudin, Elisabeth and Muyindike, Winnie and Mworozi, Kenneth and Kyohairwe, Racheal and Kananura, Keneth and Logoose, Susan and Nyehangane, Dan and Nanjebe, Deborah K T and Furlan, Valérie and Taburet, Anne-Marie and Bonnet, Maryline and Barrail-Tran, Aurélie and ANRS12292 Rifavirenz study group, ANRS12292 Rifavirenz study group},
  title = {Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf319}
}
Kostenlos starten →